查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1765417

全球罕见血液学市场

Rare Hematology
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年全球罕见血液学市场规模将达到 253 亿美元

全球罕见血液学市场规模预计在2024年为190亿美元，预计到2030年将达到253亿美元，2024年至2030年的复合年增长率为4.9%。血浆衍生因子是本报告分析的细分市场之一，预计其复合年增长率为5.0%，到分析期结束时规模将达到182亿美元。重组因子细分市场在分析期间内的复合年增长率预计为4.6%。

美国市场规模估计为 52 亿美元，中国市场预期复合年增长率为 4.6%

美国罕见血液学市场规模预计在2024年达到52亿美元。作为世界第二大经济体，中国市场规模预计到2030年将达到40亿美元，在2024-2030年的分析期间内，复合年增长率为4.6%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为4.2%。在欧洲，预计德国市场的复合年增长率为3.6%。

全球罕见血液学市场—主要趋势和驱动因素摘要

什么是稀有血液学市场？为什么它在医疗保健领域发展势头强劲？

罕见血液疾病市场专注于罕见血液疾病的诊断、治疗和管理，包括血友病、镰状细胞疾病、地中海贫血、阵发性夜间血尿症(PNH) 和各种贫血等疾病。这些疾病被归类为罕见疾病，因为它们仅影响全球一小部分人口，通常每 2,000 人中不到 1 人。儘管每种罕见血液疾病的患者数量相对较少，但由于其慢性病性质、复杂的管理要求和高昂的治疗费用，这些疾病对医疗保健系统的累积影响巨大。传统上，罕见血液疾病患者的治疗选择有限，研究投入也较低。然而，基因组学、生物技术和个人化医疗的最新趋势正在改变这种状况，导致旨在发现新治疗方法和改善患者预后的研发活动激增。因此，由于人们意识的提高、支持性政策的出台以及最先进治疗的引入，罕见血液疾病市场正在获得发展动力，这些因素正在重塑对这些挑战的管理。

患者权益团体的兴起以及医疗服务提供者、製药公司和监管机构之间合作的加强也促进了罕见血液学市场的成长。国家罕见疾病组织 (NORD) 和欧洲血液学协会 (EHA) 等组织在倡导增加研究资金、改善治疗机会和加强患者照护发挥了重要作用。这些努力鼓励製药公司投资开发治疗罕见疾病的孤儿药，儘管市场规模很小。世界各国政府推出了各种奖励，包括市场独占权、税额扣抵和加速核准流程，以鼓励开发这些专门治疗方法。因此，罕见血液学市场正在稳步涌入新的治疗选择，从基因疗法和单株抗体到先进的生技药品。这些创新解决方案的出现提高了医疗服务提供者管理罕见血液疾病的能力，改善了先前治疗选择有限或没有治疗选择的患者的生活品质。

科技进步如何改变罕见血液疾病治疗模式？

技术进步在罕见血液疾病治疗方法的发展中发挥了变革性作用，彻底改变了这些疾病的诊断和治疗方法。该领域最具突破性的创新之一是基因治疗的出现。基因治疗针对导致许多罕见血液疾病的潜在基因突变，提供了长期治疗甚至根治性的可能性。例如，在治疗血友病时，基因疗法旨在透过引入缺陷基因的功能性拷贝来减少或消除对常规凝血因子替代疗法的需要，使患者能够自然产生必要的凝血因子。同样，CRISPR-Cas9 等基因编辑技术正在被研究作为镰状细胞疾病和β地中海贫血的潜在治疗方法，并在早期临床试验中取得了令人鼓舞的结果。这些技术有可能改变罕见血液疾病的治疗模式，为传统上依赖对症治疗的患者带来希望。

除了基因治疗，生物製药和标靶治疗药物的进展也扩大了罕见血液疾病的治疗选择。例如，单株抗体已被开发用于靶向作用于参与疾病进展的特定路径和蛋白质，从而提供更精准的治疗方法并减少副作用。在诸如阵发性尿失禁（PNH）等疾病中，补体抑制剂等标靶治疗已被引入，以有效降低溶血和血栓症的风险，显着改善患者的预后。此外，个人化医疗与罕见血液疾病的结合使医疗服务提供者能够根据个体的基因图谱制定治疗方案，从而确保更高的疗效和安全性。诊断技术也在不断发展，次世代定序仪（NGS）和高通量筛检方法能够更准确、更快速地识别罕见基因突变。这些技术进步不仅有助于提高诊断的准确性，而且有助于早期发现和早期疗育，有助于更有效地管理罕见血液疾病。

哪些因素将推动罕见血液学市场采用新治疗方法？

有几个因素促使罕见血液学市场越来越多地采用新疗法，包括罕见血液病患疾病率的上升、医学研究的进步以及有利的法规结构。罕见血液病患疾病率的上升部分归因于诊断能力的提高，这使得这些疾病的检测率更高、分类更准确。随着越来越多的患者得到准确诊断，对超越传统治疗方法的创新疗法的需求也在增加。同时，医学研究的进步，特别是在基因组学和生物技术领域的进步，使得开发更有效、更有针对性的治疗方法成为可能。这些治疗方法在临床试验中的成功鼓励製药公司大力投资罕见血液学，为患者带来更多新的和改进的治疗方法选择。

推动治疗方法应用的另一个关键因素是法规环境的改善。美国食品药物管理局(FDA) 和欧洲药品管理局 (EMA) 等监管机构已意识到开发罕见疾病治疗方法所面临的独特挑战，并设立了孤儿药地位和突破性疗法认定等特殊称号。这些制度提供奖励，例如更长的市场独占期、更快的审查流程和降低的监管费用，从而对公司在罕见血液学领域进行药物开发更具吸引力。此外，患者权益团体的影响力日益增强，提高了人们对可用治疗方法的认识并扩大了资讯的获取管道，使患者及其家属能够寻求专门护理和新治疗方法。因此，这些新治疗方法越来越受到认可，尤其是在先前治疗选择有限或根本没有治疗方法选择的患者群体中。这些因素共同推动了更高的采用率，并扩大了新治疗方法在罕见血液学市场的覆盖范围。

是什么推动了全球罕见血液学市场的成长？

全球罕见血液学市场的成长受到多种因素的推动，包括对罕见疾病研究的日益关注、治疗技术的进步以及不断发展的医疗保健政策。主要成长要素之一是製药和生技公司不断增加的研发投资。在有利的监管激励措施和不断增长的患者需求的推动下，公司正在投入大量资源来发现和开发针对罕见血液疾病的创新治疗方法。因此，新型疗法正在稳步发展，从基因治疗药物和酵素替代药物到下一代生技药品和小分子药物。市场也受益于技术进步，使得更有效的疾病建模、药物筛检和临床试验成为可能，从而加快了开发进程并更快地将新治疗方法推向市场。

不断发展的医疗政策也是市场成长的关键驱动力。许多国家都推出了全国罕见疾病计画和政策，旨在改善罕见疾病（包括血液疾病）患者的诊断、治疗和照护。这些政策通常包括增加研究经费、支持专科医疗中心发展以及改善患者获得先进疗法的途径等措施。此外，学术界、产业界和患者组织之间的合作营造了更具协作性的研究环境，并加快了该领域的创新步伐。另一个成长要素是罕见血液疾病的增多，这反过来又导致需要专科治疗的患者数量增加。认知度的提高和诊断能力的提高促进了诊断率的提高，进而推动了对标靶治疗和综合护理解决方案的需求。在这些因素的共同作用下，全球罕见血液疾病市场有望持续成长，这得益于强大的创新管道、强化的法律规范以及对改善患者预后和生活品质日益增长的关注。

部分

产品类型（血浆衍生因子、重组因子）、年龄层（成人（18岁以上））、儿童（0-17岁）

受访公司范例

  • Alexion Pharmaceuticals, Inc.
  • Bayer Healthcare AG
  • CSL Behring
  • Novo Nordisk A/S
  • PRA Health Sciences
  • Shire PLC

人工智慧集成

我们正在利用可操作的专家内容和人工智慧工具来改变市场和竞争情报。

Global 特定产业SLM 的典型规范，而是建立了一个从全球专家收集的内容库，其中包括视讯录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口状况（成品和原始OEM）预测其竞争态势的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括销货成本成本 (COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他地区

第四章 比赛

简介目录
Product Code: MCP16742

Global Rare Hematology Market to Reach US$25.3 Billion by 2030

The global market for Rare Hematology estimated at US$19.0 Billion in the year 2024, is expected to reach US$25.3 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2024-2030. Plasma Derived Factors, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$18.2 Billion by the end of the analysis period. Growth in the Recombinant Factors segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.2 Billion While China is Forecast to Grow at 4.6% CAGR

The Rare Hematology market in the U.S. is estimated at US$5.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.0 Billion by the year 2030 trailing a CAGR of 4.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 4.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Rare Hematology Market - Key Trends & Drivers Summarized

What Is The Rare Hematology Market and Why Is It Gaining Momentum in Healthcare?

The Rare Hematology market focuses on the diagnosis, treatment, and management of rare blood disorders, which include conditions such as hemophilia, sickle cell disease, thalassemia, paroxysmal nocturnal hemoglobinuria (PNH), and various types of anemia. These diseases are classified as rare because they affect a small percentage of the global population, typically less than 1 in 2,000 individuals. Although the patient population for each rare hematologic condition is relatively small, the cumulative impact of these diseases on healthcare systems is significant due to their chronic nature, complex management requirements, and the high cost of treatments. Traditionally, patients with rare hematologic conditions have faced limited treatment options and low levels of research investment. However, recent advancements in genomics, biotechnology, and personalized medicine are changing this scenario, leading to a surge in research and development activities aimed at discovering novel therapies and improving patient outcomes. As a result, the Rare Hematology market is gaining momentum, driven by increasing awareness, supportive policies, and the introduction of cutting-edge treatments that are reshaping the management of these challenging conditions.

The rise of patient advocacy groups and increased collaboration between healthcare providers, pharmaceutical companies, and regulatory bodies have also contributed to the growth of the Rare Hematology market. Organizations such as the National Organization for Rare Disorders (NORD) and the European Hematology Association (EHA) have been instrumental in advocating for more research funding, better access to treatments, and enhanced patient care. These efforts have spurred pharmaceutical companies to invest in the development of orphan drugs-medications designed to treat rare conditions-despite the smaller market size. Governments around the world have introduced various incentives, including market exclusivity, tax credits, and fast-track approval processes, to encourage the development of these specialized treatments. As a result, the Rare Hematology market has seen a steady influx of new therapeutic options, ranging from gene therapies and monoclonal antibodies to advanced biologics. With the advent of these innovative solutions, healthcare providers are better equipped to manage rare hematologic disorders, improving the quality of life for patients who previously had limited or no treatment options.

How Are Technological Advancements Transforming The Treatment Landscape Of Rare Hematologic Disorders?

Technological advancements have played a transformative role in the development of therapies for rare hematologic disorders, revolutionizing the way these diseases are diagnosed and treated. One of the most groundbreaking innovations in this field is the advent of gene therapy. Gene therapies target the underlying genetic mutations responsible for many rare blood disorders, offering the potential for long-term or even curative treatments. For example, in the treatment of hemophilia, gene therapies aim to introduce a functional copy of the defective gene, enabling patients to produce the necessary clotting factors naturally, thereby reducing or eliminating the need for regular factor replacement therapy. Similarly, gene-editing technologies such as CRISPR-Cas9 are being explored as potential treatments for sickle cell disease and beta-thalassemia, with early clinical trials showing promising results. These technologies have the potential to transform the treatment paradigm for rare hematologic disorders, offering hope for patients who have historically relied on symptomatic treatments.

In addition to gene therapy, advances in biologics and targeted therapies are expanding the range of treatment options available for rare hematologic conditions. Monoclonal antibodies, for instance, have been developed to target specific pathways or proteins involved in disease progression, offering a more precise approach to treatment with fewer side effects. For conditions like PNH, targeted therapies such as complement inhibitors have been introduced, which effectively reduce hemolysis and the risk of thrombosis, significantly improving patient outcomes. Furthermore, the integration of personalized medicine into rare hematology is enabling healthcare providers to tailor treatments based on individual genetic profiles, ensuring a higher degree of efficacy and safety. Diagnostic technologies are also evolving, with next-generation sequencing (NGS) and high-throughput screening methods making it possible to identify rare genetic mutations with greater accuracy and speed. These technological advancements are not only enhancing the precision of diagnoses but also facilitating earlier detection and intervention, which are crucial for managing rare hematologic disorders more effectively.

What Factors Are Driving The Adoption Of New Treatments In The Rare Hematology Market?

Several factors are contributing to the increased adoption of new treatments in the Rare Hematology market, including the growing prevalence of rare blood disorders, advancements in medical research, and favorable regulatory frameworks. The rising incidence of rare hematologic conditions is partly due to improved diagnostic capabilities, which have led to higher detection rates and more accurate classification of these diseases. With more patients being accurately diagnosed, there is a greater demand for innovative therapies that go beyond conventional treatments. At the same time, advancements in medical research, particularly in the fields of genomics and biotechnology, are enabling the development of more effective and targeted therapies. The success of these therapies in clinical trials has spurred pharmaceutical companies to invest heavily in rare hematology, leading to an increase in the availability of new and improved treatment options for patients.

Another key driver of treatment adoption is the supportive regulatory environment. Recognizing the unique challenges associated with developing therapies for rare diseases, regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established special designations like Orphan Drug Status and Breakthrough Therapy Designation. These programs provide incentives such as extended market exclusivity, expedited review processes, and reduced regulatory fees, making it more attractive for companies to pursue drug development in the rare hematology space. Additionally, the growing influence of patient advocacy groups has led to increased awareness and better access to information about available treatments, empowering patients and their families to seek out specialized care and novel therapies. As a result, there is a rising acceptance of these new treatments, especially among patient populations that previously had limited or no therapeutic options. The combination of these factors is driving higher adoption rates and expanding the reach of new therapies within the Rare Hematology market.

What Is Driving The Growth Of The Global Rare Hematology Market?

The growth in the global Rare Hematology market is driven by several factors, including the increased focus on rare disease research, advancements in therapeutic technologies, and evolving healthcare policies. One of the primary growth drivers is the rising investment in research and development by pharmaceutical and biotechnology companies. Encouraged by favorable regulatory incentives and growing patient demand, companies are dedicating substantial resources to the discovery and development of innovative therapies for rare blood disorders. This has led to a steady pipeline of new treatments, ranging from gene therapies and enzyme replacements to next-generation biologics and small molecule drugs. The market is also benefiting from technological innovations that are enabling more effective disease modeling, drug screening, and clinical trials, thereby accelerating the development process and bringing new therapies to market more quickly.

Evolving healthcare policies are another crucial driver of market growth. Many countries have introduced national rare disease plans or policies aimed at improving the diagnosis, treatment, and care of patients with rare diseases, including hematologic conditions. These policies often include initiatives to increase research funding, support the development of specialized care centers, and improve patient access to advanced therapies. Furthermore, collaborations between academia, industry, and patient organizations are fostering a more collaborative research environment, accelerating the pace of innovation in the field. Another growth driver is the increasing prevalence of rare hematologic conditions, which is creating a larger patient pool in need of specialized treatments. Improved awareness and better diagnostic capabilities are contributing to higher diagnosis rates, which in turn are driving demand for targeted therapies and comprehensive care solutions. As these factors converge, the global Rare Hematology market is poised for continued growth, supported by a strong innovation pipeline, enhanced regulatory frameworks, and an ever-increasing focus on improving patient outcomes and quality of life.

SCOPE OF STUDY:

The report analyzes the Rare Hematology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Plasma Derived Factors, Recombinant Factors); Age Group (Adult (18+), Pediatric (0-17))

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Alexion Pharmaceuticals, Inc.
  • Bayer Healthcare AG
  • CSL Behring
  • Novo Nordisk A/S
  • PRA Health Sciences
  • Shire PLC

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Rare Hematology - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Awareness of Rare Blood Disorders Spurs Growth of the Rare Hematology Market
    • Rising Investment in Orphan Drug Development Strengthens Business Case for Rare Hematology Therapeutics
    • Advancements in Gene and Cell Therapy Propel Innovation in Rare Hematology Treatments
    • Development of Innovative Therapeutics for Hemophilia Drives Market Demand
    • Focus on Expanding Treatment Options for Sickle Cell Disease Accelerates Market Growth
    • Development of Novel Biomarkers for Blood Disorders Expands Scope of Rare Hematology Treatments
    • Emergence of Stem Cell Therapies Bodes Well for Market Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Rare Hematology Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Rare Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Rare Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Rare Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Plasma Derived Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Plasma Derived Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Plasma Derived Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Recombinant Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Recombinant Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Recombinant Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Adult (18+) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Adult (18+) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Adult (18+) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pediatric (0-17) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Pediatric (0-17) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Pediatric (0-17) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: USA 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: Canada 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • JAPAN
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Japan 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • CHINA
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: China 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • EUROPE
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Rare Hematology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Rare Hematology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Europe 15-Year Perspective for Rare Hematology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • FRANCE
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: France 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • GERMANY
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Germany 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Italy 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: UK 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 74: Rest of Europe Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Rest of Europe Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Rest of Europe 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Rest of Europe 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 80: Asia-Pacific Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Asia-Pacific Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Asia-Pacific 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Asia-Pacific 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 86: Rest of World Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of World Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Rest of World 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of World 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030

IV. COMPETITION